Another interesting question is whether combination with anti-PD-L1 antibody would confer additional benefit to MerTK inhibition in GC, given that nivolumab, an anti-PD-L1 antibody has proven efficacy in metastatic GC [20]. This evidence concerns the gene MERTK and gastric cancer.